Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies
- 802 Downloads
There is strong evidence from randomized controlled trials (RCTs) that second-generation antipsychotic (SGA) medications are associated with metabolic adverse events. However, with the recent increases in the use of SGAs worldwide and frequent off-label use, it is unclear whether these associations are generalizable to populations beyond those included in RCTs.
This review aims to characterize the impact of SGAs on the population through a systematic review of population-based studies of SGA users. Studies could examine the use of any SGA medication and any comparator group. Studies also needed to include at least one metabolic outcome such as type 2 diabetes mellitus, dyslipidemia, obesity, hypertension, or metabolic syndrome.
A systematic search process was used to identify studies for inclusion in this review. Included studies had to be population-based studies of users of any SGA medication with at least one reported metabolic outcome. Study quality was also assessed using the AMSTAR tool, and evidence was synthesized by both metabolic outcome and specific SGA medication.
In total, 15 studies were included in this review. Type 2 diabetes mellitus was the most frequently reported outcome; clozapine and olanzapine were most strongly associated with type 2 diabetes mellitus. Evidence was mixed for a moderate association between type 2 diabetes mellitus and risperidone or quetiapine. Few studies examined other metabolic outcomes, and therefore it is difficult to estimate the true effect in the population.
Population-based evidence for other SGAs and metabolic outcomes was limited. However, clozapine and olanzapine were consistently more strongly associated with metabolic adverse events than were other SGAs currently available.
Compliance with Ethical Standards
No sources of funding were used to assist in the preparation of this study.
Conflict of interest
Lauren Hirsch, Jauen Yang, Lauren Breese, and Tamara Pringsheim have no conflicts of interest that are directly relevant to the content of this study. Nathalie Jette is the holder of a Canada Research Chair in Neurological Health Services Research for work not related to this project. Scott Patten holds a competitive, peer-reviewed grant from HBI/Pfizer that is not connected to this project.
- 1.Horn M, Procyshyn R, Warburton W, Tregillus V, Cavers B, Davidson J, et al. Prescribing second-generation antipsychotic medications: practice guidelines for general practitioners. BCMJ. 2012;54(2):75–82.Google Scholar
- 2.Maglione M, Maher A, Hu J, Wang Z, Shanman R, Shekelle P, et al. Off-label use of atypical antipsychotics: an update. Rockville, MD: Agency for Healthcare Research and Quality; 2011. Contract No.: 11-EHC087.Google Scholar
- 8.Khanna P, Suo T, Komossa K, Ma H, Rummel-Kluge C, El-Sayeh HG, Leucht S, Xia J. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2014;(1):CD006569. doi: 10.1002/14651858.CD006569.pub5.
- 11.Effective Practice and Organisation of Care (EPOC). Data extraction and management. EPOC Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services; 2013. Available at: http://epoc.cochrane.org/epoc-specific-resources-review-authors.
- 12.Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011.Google Scholar
- 13.Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle–Ottawa Scale for assessing the quality of nonrandomized studies in meta-analysis. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 1 May 2016.
- 20.Correll C, Joffe B, Rosen L, Sullivan T, Joffe R. Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepresseant use in a non-elderly adult sample: results from a claims-based inception cohort study. World Psychiatry. 2015;14(1):56–63.CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Rubin DM, Kreider AR, Matone M, Huang YS, Feudtner C, Ross ME, Localio AR. Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among Medicaid-enrolled youths. JAMA Pediatr. 2015;169(4):e150285. doi: 10.1001/jamapediatrics.2015.0285.CrossRefPubMedGoogle Scholar
- 29.Sacchetti E, Turrina C, Parrinello G, Brignoli O, Stefanini G, Mazzaglia G. Incidence of diabetes in a general practice population: a database cohort study on the relationship with haloperidol, olanzapine, risperidone or quetiapine exposure. Int Clin Psychopharmacol. 2005;20(1):33–7.CrossRefPubMedGoogle Scholar
- 31.McEvoy J, Meyer J, Goff D, Nasrallah HA, Davis S, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19–32.CrossRefPubMedGoogle Scholar